Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España
Actualizado agosto 2023
Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)
Para iniciar la búsqueda, teclee el texto en la barra a continuación.
| EudraCT-Number | NCT | CÓDIGO-ESTUDIO | TÍTULO ESTUDIO | FASE | INDICACIÓN | ESTADO | MEDICACIÓN | CENTRO | PROMOTOR |
|---|---|---|---|---|---|---|---|---|---|
| 2018-004334-15 | 4234113 | SC103 | A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors | Phase I | Thyroid & HNSCC, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selectedadvanced/metastatic solid tumors | RECLUTANDO | SO-C101 Pembrolizumab | H.U. Vall d´Hebron(BCN) H. Sanchinarro (Madrid) | SOTIO |
| UNK | 4985604 | DAY101-102 | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | Phase I/II | This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway. | RECLUTANDO | Tovorafenib Pimasertib | H. Clinic Barcelona H. U. Vall d'Hebron H. U. Ramón y Cajal | Day One Biopharmaceuticals, Inc. |
| UNK | 4731467 | FW-2020-1 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumor | Phase I/II | Cohort: Papillary Thyroid Cancer | RECLUTANDO | CM-24 Nivolumab, Nab paclitaxel Gemcitabine | H. Vall d' Hebron H. 12 Octubre H. Quiron Salud Valencia Start_Sanchinarro(Madrid) | Famewave Ltd Bristol-Myers Squibb |
| 2018-001066-42 | 3753919 | GETNE-T1812 | A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial | Phase II | This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers. Cohort 1: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle. Cell and poorly-differentiated thyroid carcinoma (DTC). Cohort 2: Advanced medullary thyroid carcinoma (MTC). Cohort 3: Advanced anaplastic thyroid cancer (ATC) | RECLUTANDO | Durvalumab Tremelimumab | C.U.N. H.U. Vall d´Hebron (Barcelona) ICO Hospitalet H.U. Morales Meseguer (Murcia) H.U. Ramón y Cajal (Madrid) H.U. 12 de Octubre (Madrid) H.U. La Paz (Madrid) H.U. Virgen de la Victoria (Málaga) H.U. Clínic (Barcelona) M.D. Anderson (Madrid) H.U. Sanchinarro (Madrid) H.U. Clínico San Carlos (Madrid) C.H. Castellón IVO Valencia H.U. Alvaro Cunqueiro (Vigo) | Spanish Group of Neuroendocrine Tumors (GETNE) |
| 2016-003616-13 | 3093116 | TPX-0005-01 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Phase II (in Spain) | Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts. | RECLUTANDO | Repotrectinib (TPX-0005) | C.U.N. H.U. Dexeus (Barcelona) H.U. Vall d´Hebron (Barcelona) M.D. Anderson (Madrid) Start_F.J.Díaz (Madrid) Start_Sanchinarro (Madrid) H.U. 12 de Octubre (Madrid) IVO Valencia | Turning Point Therapeutics, Inc. |
| 2015-002067-41 CTIS: 2022-500397-34-00 | 2628067 | 3475-158 | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | Phase II | Thyroid Carcinoma Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded) | RECLUTANDO | Pembrolizumab | H.U. Vall d´Hebron (Barcelona) H.U. Ramón y Cajal (Madrid) H.U. 12 de Octubre (Madrid) | Merck Sharp & Dohme Corp |
| 2020-001847-16 | 4589845 | BO41932 | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | Phase II | Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first. | RECLUTANDO | Pralsetinib Entrectinib Belvarafenib | H.U. Vall d´Hebron (Barcelona) C.U.N. H.U. 12 de Octubre (Madrid) H.U. La Paz (Madrid) H.U. La Fe (Valencia) | Hoffmann-La Roche |
| UNK | 5660954 | GETNE-T2216 | Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | Phase II | CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractory | RECLUTANDO | Cabozantinib | H. U. Central de Asturias H. U. Rey Juan Carlos C. H. U. A Coruña H. U. Vall d'Hebron H. Clínic de Barcelona H. U. Ramón y Cajal H. Clínico San Carlos H. U. 12 de Octubre H. Morales Meseguer (Murcia) C. A. U. de Salamanca | Grupo Espanol de Tumores Neuroendocrinos |
| 2019-001978-28 | 4211337 | J2G-MC-JZJB | A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Phase III | Male or female patients with progressive, advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer | RECLUTANDO | Selpercatinib Cabozantinib Vandetanib | H.U. Virgen de la Victoria (Málaga) H.U. Clínico San Carlos (Madrid) H.U. 12 de Octubre (Madrid) H.U. La Paz (Madrid) H.U. Ramón y Cajal (Madrid) H.U. Gregorio Marañón (Madrid) ICO Girona ICO Hospitalet H.U. Vall d´Hebron (Barcelona) C.U.N. H.U. Miguel Servet (Zaragoza) | Loxo Oncology, Inc |
| 2020-005269-15 | 4760288 | CO42865 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) | Phase III | RET-Mutated Medullary Thyroid Cancer (MTC) is a form of thyroid carcinoma which originates from parafollicular cells and which produce the hormone calcitonin. | RECLUTANDO | Pralsetinib Cabozantinib Vandetanib | H. Clínico de Santiago de Compostela C.U.N. H.U. Vall d´Hebron (Barcelona) H. Clínic (Barcelona) H.U. Ramón y Cajal (Madrid) H. Sanchinarro (Madrid) H.U. Virgen del Rocío (Sevilla) H. Regional de Málaga MD Anderson (Madrid) H.U. Reina Sofía (Córdoba) | Hoffmann-La Roche |
| UNK | 3906331 | J2G-OX-Y001 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | Expanded Access | Medullary Thyroid Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration | DISPONIBLE | Selpercatinib | H.U. Vall d´Hebron (Barcelona) Start_Sanchinarro (Madrid) | Loxo Oncology, Inc. |
| N.A | 3765333 | REGETNE-Tiroides | Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic | Descriptive Observational | NA | RECLUTANDO | NA | H.U. Vall d´Hebron (Barcelona) | Grupo Espanol de Tumores Neuroendocrinos |
Puede seleccionar el número de filas a representar entre: 4, 8 o 10